Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

Abstract Introduction The main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6 months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis (RA) in a real-world setting. Secondary objectives aimed to des...

Full description

Bibliographic Details
Main Authors: Jean Darloy, Nicolas Segaud, Jean-Hugues Salmon, Jean-Paul Eschard, Vincent Goëb, Xavier Deprez, Marie-Hélène Guyot, Eric Houvenagel, Nicolas Lecuyer, Laurent Marguerie, Samuel Gally, David Pau, Isabelle Idier, Guy Baudens, René-Marc Flipo
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-01-01
Series:Rheumatology and Therapy
Subjects:
Administration route
Rheumatoid arthritis
Subcutaneous
Switch
Tocilizumab
Online Access:http://link.springer.com/article/10.1007/s40744-018-0138-y

Internet

http://link.springer.com/article/10.1007/s40744-018-0138-y

Similar Items